Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
Portfolio Pulse from
Novartis is set to present significant new data from its Phase III Scemblix® ASC4FIRST and Kisqali® NATALEE trials at major medical conferences, highlighting its ongoing research and development efforts.
November 25, 2024 | 6:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novartis will present new 96-week results from its Phase III Scemblix® ASC4FIRST trial and late-breaking analysis from the Phase III Kisqali® NATALEE trial at major medical conferences, potentially impacting its stock positively.
The presentation of new data from Phase III trials at major conferences like ASH and SABCS is likely to be viewed positively by investors, as it demonstrates Novartis's progress in drug development and potential future revenue streams.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90